Adamas Pharma (ADMS) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharma (NASDAQ: ADMS) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $22 million versus the consensus estimate of $21.95 million.
Full year 2021 expense guidance:
For full year 2021, Adamas is reiterating its estimates for R&D, SG&A and stock-based compensation expenses as set forth below:
|
| Full Year 2021 |
R&D expenses |
| $5 million -- $10 million1 |
SG&A expenses |
| $110 million -- $120 million2 |
Total operating expenses |
| $115 million -- $130 million3 |
1Includes stock-based compensation expense of $1 million.
2Includes stock-based compensation expense of $8 million.
3Includes stock-based compensation expense of $9 million.
For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
